VEGFA and age-related macular degeneration: However, two of these monoclonal antibodies, bevacizumab (Avastin® and ranibizumab (Lucentis®), and the fusion protein aflibercept (Eylea®) show anti-VEGF properties and are used to treat neovascular (wet) age-related macular degeneration (AMD) and diabetic retinopathy.